BostonGene
Biotechnology ResearchMassachusetts, United States201-500 Employees
BostonGene, based in Waltham, Massachusetts, operates in biotechnology research by integrating diverse data types with artificial intelligence to study cancer and the immune system. Its core AI framework combines genomic, transcriptomic, immune, and clinical-outcome information to map the tumor microenvironment and generate biologically grounded insights. Built and validated through a broad real-world clinical network, the approach supports target discovery, trial design, and patient care decisions across stages of development. BostonGene collaborates with leading cancer centers, including MD Anderson Cancer Center, Memorial Sloan Kettering, Dana Farber Cancer Institute, and the Mayo Clinic, and maintains strategic partnerships with pharmaceutical companies such as AstraZeneca, Johnson & Johnson, and Takeda. The company has contributed to more than 200 publications in top peer-reviewed journals, underscoring its presence in oncology and immunology research. In May 2026, BostonGene announced the launch of an AI-driven harmonized tumor microenvironment classification system at the ASCO Annual Meeting to improve patient stratification for immunotherapy and targeted therapies across solid tumors.
1-888-653-2347 
support@leadiq.com 
